Big improvements in survival among patients with multiple myeloma were reported at the European Hematology Association annual congress in Barcelona by Greek researchers looking at the past decade of t
Evangelos Terpos, University of Athens
Big improvements in survival among patients with multiple myeloma were reported at the European Hematology Association annual congress in Barcelona by Greek researchers looking at the past decade of therapy with the novel agents: thalidomide, lenalidomide and bortezomib in the “real world” setting. Professor Evangelos Terpos from the University of Athens discusses his groups findings on bone metabolism under novel agent therapy and assesses the impact of these drugs on survival among patients in Greece.
LISTEN
[audio:https://www.audiomedica.com/podcasting/oncology/100628EvangelosTerposPODCAST.mp3]
Related Episodes
Rituximab Maintenance Cuts Follicular Lymphoma Recurrence Risk In Half — Phase III PRIMA Study Results
Patients in the PRIMA study who had achieved remissions for their follicular lymphoma by means of immunochemotherapy had only half the risk of recurrence if they also received maintenance therapy with